As per MRFR analysis, the South Korea Gene Editing Market Size was estimated at 143.8 (USD Million) in 2023. The South Korea Gene Editing Market Industry is expected to grow from 173.4 (USD Million) in 2024 to 1,075 (USD Million) by 2035. The South Korea Gene Editing Market CAGR (growth rate) is expected to be around 18.041% during the forecast period (2025 - 2035).
Advancements in biotechnology and increased investment from both the public and private sectors are driving significant growth in the South Korea Gene Editing Market. Innovation has been stimulated by the government's proactive approach to fostering research and development, with initiatives that concentrate on the establishment of a robust ecosystem in a robust biotechnology.
The Ministry of Science and ICT, in collaboration with a variety of research institutions, is committed to the advancement of gene editing technologies, including CRISPR, with the objective of enhancing healthcare and agriculture. This not only emphasizes the government's dedication but also encourages collaboration between academia and industry, which is crucial for the development of effective gene therapies.
Key sectors such as agriculture, healthcare, and environmental management are being prioritized as opportunities in the South Korean gene editing market are investigated. The utilization of gene editing for crop enhancement is becoming increasingly popular in South Korea as a means of addressing food security concerns, particularly in the context of climate change.
In the same vein, gene editing technology is being employed to advance healthcare, particularly in the areas of personalized medicine and rare disease treatments. The social acceptance of genetically modified products is also on the rise, which enables the widespread application of these technologies. Local biotech firms are collaborating with global actors to improve their research capabilities and create innovative gene editing applications, as evidenced by recent trends.
This has increased partnerships and collaborations within South Korea. Additionally, educational initiatives and awareness campaigns are being implemented to enhance the public's understanding of the safety and advantages of gene editing technologies. In general, these market trends are indicative of a dynamic landscape in South Korea that is dedicated to utilizing the potential of gene editing to resolve critical challenges in agriculture and health, thereby establishing the country as a key player in this evolving field.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The South Korea Gene Editing Market is experiencing substantial growth driven by heightened investment in Research and Development (R&D) activities. The South Korean government has pledged significant financial support to biotechnology, with a plan to invest approximately USD 1.1 billion in the biotechnology sector over the next five years.
This initiative aims to enhance global competitiveness and innovation in gene editing technologies. Prominent universities and institutions, such as KAIST (Korea Advanced Institute of Science and Technology), are also increasing their focus on genome editing research. In recent years, KAIST reported a rise of over 50% in research publications related to CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technologies, underscoring a robust academic interest and foundational advancement in this field. As research progresses and novel applications are discovered, the market is anticipated to flourish, further fueled by exciting breakthroughs related to genetic treatments and agricultural advancements.
The rising incidence of genetic disorders in South Korea acts as a significant driver for the South Korea Gene Editing Market Industry. According to recent statistics from the Korean National Institute of Health, around 1 in 400 individuals in South Korea is affected by a genetic disorder, representing a growing need for effective therapies.
Gene editing technologies, particularly CRISPR, are being explored as potential solutions to treat various genetic conditions such as muscular dystrophy and cystic fibrosis. The increasing awareness and demand for genetic therapies have prompted collaborations among major pharmaceutical firms and research institutions. Noteworthy organizations like Samsung Biologics are actively investing in gene editing solutions, as they recognize the implications of genetically engineered treatments on healthcare. This growing recognition and urgency to address genetic disorders encourage advancements in gene editing, thereby propelling market growth.
The South Korea Gene Editing Market is also significantly shaped by the expansion of agricultural applications of gene editing technology. With the global population projected to reach 10 billion by 2050, South Korea is prioritizing sustainable food production to meet future food demands.
The government's recent policies aimed at promoting genetically modified organisms (GMOs) have facilitated research in gene editing for agricultural enhancements. Reports indicate that South Korea's agricultural productivity has the potential to increase by up to 30% through gene editing interventions, specifically in developing drought-resistant and pest-resistant crop varieties. Establishments like the Rural Development Administration (RDA) have been instrumental in pioneering research on gene editing technologies for crop improvement. Efforts are underway to integrate gene editing in South Korean farming practices, which is expected to accelerate the adoption of gene editing solutions, consequently invigorating the market.
The supportive regulatory environment in South Korea significantly fosters the growth of the South Korea Gene Editing Market Industry. The Ministry of Food and Drug Safety has introduced regulatory frameworks that streamline the approval process for gene editing technologies, thereby reducing the time required for research and commercialization.
For example, the newly implemented 'Genome Editing Guide' aims to provide clarity on regulatory requirements for gene editing projects, facilitating a smoother transition from lab to market. As safety assessments are efficiently conducted, the reliance on gene editing technologies in various sectors, such as healthcare and agriculture, grows. The leading biopharmaceutical firm, Hanmi Pharmaceutical, has hailed the regulatory advancements as instrumental in accelerating its pipeline of gene therapies. The supportive policies bolster investor confidence, leading to increased funding and collaborative efforts in gene editing research, thus significantly driving market growth.
The Technology segment of the South Korea Gene Editing Market is a rapidly evolving area, with significant contributions to biotechnology and life sciences. Among the most notable technologies is CRISPR, which has revolutionized the field by providing a cost-effective and precise method for gene editing, drawing considerable interest from both academic and commercial sectors.
Its broad applications, ranging from agriculture to medicine, highlight its importance in enhancing crop resilience and developing treatments for genetic disorders. TALEN technology also plays a crucial role, particularly in gene therapy applications where precise modifications are necessary. Its ability to target specific genetic sequences allows for tailored therapeutic solutions, making it a vital component in research aimed at addressing complex genetic diseases.
ZFN, while slightly older in the market, continues to be influential due to its capability to create double-strand breaks at specified gene locations, facilitating gene disruption or correction. This technology sees significant utilization in agricultural biotechnology, where it is used to introduce desirable traits into crops. Antisense technology, which operates differently by using synthetic strands of nucleic acids to bind to and modulate gene expression, is noteworthy for its potential in treating various diseases, especially those linked to single-gene defects.
This segment is gaining traction in South Korea, where national biotech initiatives have fostered research in genetic disorders and cancer treatment, offering new therapeutic avenues for patients. Additionally, the broader others’ category encompasses emerging technologies that aim to complement or improve existing methodologies, ensuring that South Korea remains at the forefront of gene editing innovation.
The country’s supportive regulatory environment and government grants for Research and Development further enhance the landscape, positioning South Korea as a leader in global gene editing advancements. Overall, the Technology segment promises substantial growth, driven by ongoing innovations and applications across health, agriculture, and environmental sustainability, solidifying its pivotal role within the South Korea Gene Editing Market.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The South Korea Gene Editing Market, particularly within the Application segment, exhibits promising potential driven by advancements in technology and increased investments in Research and Development. Genetic Engineering stands out as an essential application, enabling the manipulation of DNA to achieve desired traits in organisms, which plays a crucial role in agriculture and pharmaceuticals.
Gene Therapy, another pivotal area, focuses on correcting genetic disorders by introducing, removing, or altering genetic material within a patient’s cells, showcasing significant promise for treating inherited diseases and cancers. Cell Line Engineering is equally important as it provides frameworks for developing monoclonal antibodies and vaccines, crucial in biopharmaceutical production and research.
Additional applications involving various techniques and processes cater to niche markets, enhancing the versatility of the South Korea Gene Editing Market. The rising prevalence of genetic disorders, coupled with an aging population and expanding biotechnological infrastructure, acts as a substantial driver for market growth. Despite challenges such as ethical considerations and regulatory hurdles, the opportunities within these applications are set to expand, reflecting the dynamic evolution of the South Korea Gene Editing Market.
The South Korea Gene Editing Market is witnessing substantial growth, particularly in the Method segment, which encompasses various approaches like Ex-vivo and In-vivo techniques. Ex-vivo gene editing allows for the modification of cells outside the body and has seen increased application in Research and Development for therapeutic purposes, making it significant in areas like cancer treatment and genetic disorders.
Meanwhile, In-vivo gene editing involves direct modification within the living organism, which holds promise for genetic therapies and has been instrumental in advancements in agricultural biotechnology. The South Korean government has been actively supportive of gene editing initiatives, facilitating research and fostering collaboration between academic institutions and industry players.
With a focus on innovative healthcare solutions and agricultural advancements, both Ex-vivo and In-vivo methods are driving factors in the South Korea Gene Editing Market, aligning with national priorities for improving public health and food security. As more discoveries emerge, these methods will play crucial roles in shaping the future landscape of gene editing technologies.
The end-user segment of the South Korea Gene Editing Market showcases a diverse landscape with significant contributions from various sectors. Biotechnology and Pharmaceutical Companies largely drive the market, focusing on developing genetic therapies and innovative treatments that address critical healthcare challenges.
Contract Research Organizations (CROs) play a vital role as enablers, facilitating clinical trials and offering specialized research services that support the rapid advancement of gene editing technologies. Meanwhile, Academic and Government Research Institutes, with their strong emphasis on Research and Development, contribute to the foundational knowledge and groundbreaking discoveries needed for the evolution of gene editing applications.
This segment benefits from South Korea's robust commitment to biotechnology, characterized by substantial government support for scientific research and development initiatives. The increasing prevalence of genetic disorders and the growing demand for personalized medicine further underscore the significance of this segment in addressing the health needs of the population. Additionally, advancements in CRISPR technology continue to fuel opportunities within this space, reflecting a strong momentum for growth and innovation across the end-user segment in South Korea's Gene Editing Market.
The South Korea Gene Editing Market has witnessed significant advancements and competitive dynamics in recent years, driven by the rapid evolution of biotechnology and increasing investment in research and development. This burgeoning market reflects the nation's commitment to being at the forefront of genetic research, leveraging cutting-edge technologies such as CRISPR, genome sequencing, and synthetic biology.
The competitive landscape is characterized by a blend of established industry leaders and innovative startups, all striving to carve out their unique niches. As companies enhance their capabilities and expand their product offerings, the market is expected to witness further consolidation and strategic collaborations that foster growth and innovation, bolstering South Korea's position as a key player in the global gene editing arena.
Hana Genomics has emerged as a prominent entity in the South Korea Gene Editing Market, capitalizing on its strong research capabilities and a dedicated focus on genetic therapies. The company has cultivated strategic partnerships with academic institutions and research organizations, allowing it to tap into the latest scientific advancements in gene editing technologies.
By concentrating on innovative solutions tailored to address genetic disorders, Hana Genomics has developed a reputation for excellence in delivering effective therapies that resonate with the healthcare community. The strengths of Hana Genomics lie in its pioneering approaches and ability to rapidly adapt to changes in consumer demands and scientific breakthroughs, solidifying its competitive edge and contributing to its expanding presence in the market.
Samsung Biologics has positioned itself as a formidable player in the South Korea Gene Editing Market with a comprehensive portfolio of services, particularly in biologics and therapeutic development. With key products spanning a range of biologics-related offerings, the company maintains a strong footprint through its state-of-the-art manufacturing facilities, which profoundly enhance its capacity and efficiency.
The synergy between Samsung Biologics and its parent company creates significant advantages in terms of resource allocation and technological expertise, leading to strategic mergers and acquisitions that bolster its market presence. By leveraging these strengths, the company is able to offer innovative solutions that align with the demands of biopharmaceutical partners, further establishing itself as a leader in gene editing advancements within the South Korean landscape.
The South Korea Gene Editing Market has seen significant developments recently, particularly with companies like Hana Genomics, Samsung Biologics, and Sillajen leading the way in Research and Development initiatives. In July 2023, Celltrion announced advancements in its gene therapy platforms, enhancing its position in the expanding gene editing landscape.
Major companies such as Medipost and Genexine are also experiencing growth, contributing to the increase in market valuation, influenced by robust funding and government support for innovative biotechnologies. In September 2023, Eirgenix entered into a strategic partnership with Toolgen to advance research capabilities in gene editing technologies, reflecting a trend of collaboration in the sector.
Over the past two to three years, the South Korean government has committed substantial resources to foster innovation in biotechnology, pushing the market's growth trajectory. Over the last year, Hugel and Seegene have expressed intentions to explore gene editing applications in personalized medicine, further positioning themselves within a competitive marketplace. Such endeavors signify an ongoing evolution in South Korea’s gene editing sector, aligning with national goals to enhance healthcare solutions and improve therapeutic outcomes.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 143.8(USD Million) |
| MARKET SIZE 2024 | 173.4(USD Million) |
| MARKET SIZE 2035 | 1075.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.041% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Hana Genomics, Samsung Biologics, Sillajen, Medipost, Genomictree, Toolgen, Celltrion, Eirgenix, Hugel, Seegene, NexGene, MediPost, Genexine, Korean Bioprocessing Institute |
| SEGMENTS COVERED | Technology, Application, Method, End User |
| KEY MARKET OPPORTUNITIES | Growing demand for precision medicine, Advancements in agricultural biotech, Increased investment in research funding, Rising prevalence of genetic disorders, Enhanced collaboration with biotech firms |
| KEY MARKET DYNAMICS | Regulatory advancements, Increasing R&D investment, Rising demand for healthcare innovation, Growing public awareness, Collaboration with global firms |
| COUNTRIES COVERED | South Korea |
Frequently Asked Questions (FAQ) :
The South Korea Gene Editing Market is expected to be valued at 173.4 million USD in 2024.
By 2035, the South Korea Gene Editing Market is anticipated to reach a value of 1,075 million USD.
The expected CAGR for the South Korea Gene Editing Market from 2025 to 2035 is 18.041%.
By 2035, the CRISPR technology segment is projected to dominate the market, reaching approximately 430 million USD.
The TALEN technology segment is expected to be valued at around 250 million USD by 2035.
Key players in the market include Hana Genomics, Samsung Biologics, and Sillajen, among others.
The ZFN technology segment is expected to be valued at 30 million USD in 2024.
Potential challenges may include regulatory hurdles and ethical considerations surrounding gene editing technologies.
The Antisense technology segment is projected to reach around 90 million USD by 2035.
Increasing investment in research and development as well as advancements in gene editing technologies are likely to drive market growth.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
